Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for formulation patents
Australian High Court hears high-stakes matter of PTE eligibility of formulation patents Australian High Court hears high-stakes matter of PTE eligibility of formulation patents Reviewed by Dr Claire Gregg on Wednesday, June 17, 2026 Rating: 5
Otsuka seeks to appeal decision to deny PTEs for formulation patents in Australia Otsuka seeks to appeal decision to deny PTEs for formulation patents in Australia Reviewed by Dr Claire Gregg on Monday, March 02, 2026 Rating: 5
Formulation patents no longer eligible for PTE in Australia Formulation patents no longer eligible for PTE in Australia Reviewed by Dr Claire Gregg on Saturday, December 06, 2025 Rating: 5
When your formulation IP is beyond compare (T 0722/24) When your formulation IP is beyond compare (T 0722/24) Reviewed by Dr Rose Hughes on Monday, August 25, 2025 Rating: 5
No back-pedaling on prosecution disclaimers (Azurity v. Alkem, Fed. Cir. Case No. 23-1977) No back-pedaling on prosecution disclaimers (Azurity v. Alkem, Fed. Cir. Case No. 23-1977) Reviewed by Dr Rose Hughes on Tuesday, April 22, 2025 Rating: 5
BREAKING: Supreme Court confirms no hard line on inventive step test in finding Cialis dosage patent obvious BREAKING: Supreme Court confirms no hard line on inventive step test in finding Cialis dosage patent obvious Reviewed by Dr Rose Hughes on Wednesday, March 27, 2019 Rating: 5
The rise of "obvious to try" is over as Court of Appeal finds CIALIS dosage regimen patent obvious The rise of "obvious to try" is over as Court of Appeal finds CIALIS dosage regimen patent obvious Reviewed by Annsley Merelle Ward on Sunday, November 05, 2017 Rating: 5
UPDATE: Birss J refuses permission to appeal in Genentech's Herceptin battle UPDATE: Birss J refuses permission to appeal in Genentech's Herceptin battle Reviewed by Annsley Merelle Ward on Friday, May 23, 2014 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.